A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy
Sponsor: Thomas Jefferson University
Listed as NCT04111172, this PHASE2 trial focuses on Clinical Stage II Gastric Cancer AJCC v8 and Clinical Stage IIA Gastric Cancer AJCC v8 and remains ongoing. Sponsored by Thomas Jefferson University, it has been updated 15 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
Status: Suspended → Active Not Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Suspended PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Suspended PHASE2
▶ Show 10 earlier versions
-
Feb 2024 — Jun 2024 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE2
-
Dec 2022 — Dec 2023 [monthly]
Recruiting PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Thomas Jefferson University
For direct contact, visit the study record on ClinicalTrials.gov .